Skip to content
Patient perspectives are vital to inform health policy. One agency where such input is particularly crucial is the Centers for Medicare and Medicaid Services […]
Patient organization engagement of CMS is more important than ever Read More »
The Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher (PPRV) Program was top of mind during BIO’s March Patient Advocacy Coffee
The time has come for Congress to pass legislation to prevent pharmacy benefit managers (PBMs) from inflating drug costs, limiting patient access to drugs,
House members urge passage of reforms at PBM hearing Read More »
The Centers for Medicare & Medicaid Services (CMS) recently announced the 2025 selection of 15 drugs covered under Medicare Part D for price “negotiations”
The role of the patient voice in CMS drug price ‘negotiation’ Read More »
February 28 is Rare Disease Day, and in observance, the Biotechnology Innovation Organization (BIO) is highlighting how it is working with member companies to
BIO celebrates release of FDA Rare Disease Innovation Hub 2025 strategic plan Read More »
Drug development in the rare disease space has seen a vast amount of innovation in recent years, with a number of groundbreaking therapies coming
Goodwin Rare Disease Symposium: ‘So much opportunity, so much unmet need’ Read More »
Seeking biotech-friendly policy from the new administration and Congress will be daunting and perhaps confusing, but there are still a lot of potential wins
BIO CEO 2025: Challenges and opportunities in the new administration Read More »
Reforms to prevent middlemen from driving up drug prices and legislation encouraging the development of oral medications and rare disease treatments were called top
What BIO’s watching in the new Congress Read More »
Legislation introduced last year to ease widespread commercialization of sustainable aviation fuel (SAF) was reintroduced Jan. 16 as one of the early measures proposed
Farm to Fly Act reintroduced in Senate would give SAF wings Read More »
Pharmacy benefit managers (PBMs) make billions in profit while driving up the price of prescription drugs with markups that can exceed 1,000%, according to
FTC’s second report on PBMs blasts drug price markups of 1,000% Read More »
